

## ORIGINAL ARTICLE

## Changes in the atherogenic risk factor profile according to degree of weight loss

T Reinehr, W Andler

Arch Dis Child 2004;89:419–422. doi: 10.1136/adc.2003.028803

See end of article for authors' affiliations

Correspondence to:  
Dr T Reinehr, Vestische  
Kinderklinik, University  
of Witten-Herdecke,  
Dr F Steiner Str. 5, 45711  
Datteln, Germany; T.  
Reinehr@kinderklinik-  
datteln.de

Accepted 21 August 2003

**Background:** The atherogenic risk factor profile in obese subjects is characterised by hypertension, reduced high density lipoprotein (HDL) cholesterol, increased low density lipoprotein (LDL) cholesterol and triglycerides, and insulin resistance.

**Aims:** To examine the amount of weight reduction required to improve the atherogenic profile.

**Methods:** Changes of systolic and diastolic blood pressure, HDL and LDL cholesterol, triglycerides, and insulin resistance, based on the HOMA model over a one year period were studied in obese children, who attended the intervention programme "Obeldicks". The children were divided into four groups according to the change in body mass index standard deviation score (SDS-BMI): group I, increase in SDS-BMI; group II, decrease in SDS-BMI  $<0.25$ ; group III, decrease in SDS-BMI  $\geq 0.25$ – $<0.5$ ; group IV, decrease in SDS-BMI  $\geq 0.5$ .

**Results:** A total of 130 children (mean age 10.7 years, range 4–15; mean SDS-BMI 2.5, range 2.0–4.0) were studied. The four groups did not differ in age, gender, or degree of overweight (SDS-BMI). An increasing SDS-BMI (group I:  $n=20$ ) was followed by a significant increase in insulin resistance (HOMA). Systolic and diastolic blood pressure, LDL cholesterol, triglycerides, and insulin resistance (HOMA) decreased significantly while HDL cholesterol increased significantly in group IV ( $n=37$ ). LDL cholesterol also decreased significantly in group III ( $n=40$ ); there was no significant change of the other parameters in groups I, II, and III.

**Conclusion:** Over a time period of one year increasing weight in obese children leads to an increase in insulin resistance. Weight loss is associated with an improvement in the atherogenic profile and in insulin resistance, but only if the SDS-BMI decreases by at least 0.5 over a one year period.

The increasing prevalence of obesity in childhood and adolescence poses an ever increasing problem.<sup>1</sup> Obese children tend to become obese adults.<sup>2</sup> Some obese subjects go on to display a characteristic profile of hypertension, reduced high density lipoprotein (HDL) cholesterol, increased low density lipoprotein (LDL) cholesterol and triglycerides, and insulin resistance (metabolic syndrome).<sup>3–4</sup> Such a metabolic, or atherogenic, profile may create favourable conditions for atherogenic cardiovascular disease and non-insulin dependent diabetes.<sup>5–6</sup> Early features of the metabolic syndrome, and insulin resistance, may be shown in some obese subjects during childhood.<sup>7–9</sup>

The appropriate approach to reducing the obesity related health risk is to reduce body weight. In adults, a reduction of body mass index (BMI) of at least 1 over the time period of one year leads to a lower rate of morbidity.<sup>10</sup> Interpretation of these studies in the childhood population is difficult since BMI increases in healthy normal weight children with increasing age.<sup>11</sup>

In childhood, there only few studies showing that weight reduction leads to an improvement of the atherogenic risk-factor profile.<sup>8–12</sup> In childhood, the amount of weight reduction required to improve the atherogenic risk-factor profile has not yet been studied.<sup>13–14</sup> We studied changes in the atherogenic risk-factor profile and insulin resistance in obese children over the time period of one year according to degree of SDS-BMI loss.

## MATERIALS AND METHODS

We examined all children suffering from obesity, who attended the intervention programme "Obeldicks"<sup>15–16</sup> for obese children between 1999 and 2002. The one year outpatient training "Obeldicks" is based on a programme of

physical exercise, nutrition education (high carbohydrate, fat reduced diet), and behaviour therapy including individual psychological care of the child and its family. An interdisciplinary team of paediatricians, diet assistants, psychologists, and exercise physiologists is responsible for the training.

Children with endocrine disorders, familial hyperlipidaemia, or syndromal obesity were excluded from the study. Obesity was defined according to the BMI 97th centile passing through BMI values of 30 kg/m<sup>2</sup> at the age of 18 years using population specific data.<sup>17</sup> Height and weight were measured at baseline and one year later. The weight status was recorded as BMI and the BMI standard deviation score (SDS-BMI) using the LMS method.<sup>17–18</sup> The M and S curves correspond to the median and coefficient of variation body mass index for German children at each age and gender, whereas the L curve allows for the substantial age dependent skewness in the distribution of body mass index. The assumption underlying the LMS method is that after Box-Cox power transformation the data at each age are normally distributed.<sup>11–18</sup>

Systolic and diastolic blood pressure, fasting HDL and LDL cholesterol, triglycerides, insulin, and blood glucose were measured at baseline and one year later. Systolic and diastolic blood pressure were measured after a 10 minute rest in the supine position by using a sphygmomanometer. Measurements were done twice and averaged. HDL and LDL cholesterol were measured by an enzymatic test (LDL-C Plus and HDL-C Plus respectively), triglycerides by a

**Abbreviations:** BMI, body mass index; HDL, high density lipoprotein; HOMA, homoeostasis model assessment; LDL, low density lipoprotein; SDS, standard deviation score

**Table 1** The atherogenic risk-factor profile of the 130 children at baseline

Hypertension*	45%
Decreased HDL cholesterol†	5%
Increased LDL cholesterol‡	13%
Hypertriglyceridaemia§	32%
HOMA >4	36%

\*Blood pressure >95th centile.<sup>37</sup>

†HDL cholesterol: &lt;35 mg/dl.

‡LDL cholesterol: &gt;150 mg/dl.

§Triglycerides &gt; 100 mg/dl &lt; 10 years respectively &gt;150 mg/dl ≥ 10 years.

colorimetric test (Vitros Trig-Analyseplättchen). Insulin was measured by microparticle enzyme assay (Abboth). Blood glucose was determined by colorimetric test (Vitros GLU-Analyse-plättchen). Intra-assay and interassay coefficients of variation were <4.0% in all methods. Homeostasis model assessment (HOMA) was used to detect the degree of insulin resistance;<sup>19</sup> the resistance can be assessed from the fasting glucose and insulin concentrations by the formula: resistance (HOMA) = insulin [mU/l] × glucose [mmol/l]/22.5. Insulin resistance was defined by HOMA >4. The cut off point of 4 was chosen because: (1) the lower limit of the top quintile of HOMA distribution values is below 4 in normal weight subjects;<sup>20</sup> and (2) prospective study has shown that subjects with HOMA <4 are unlikely to develop non-insulin dependent diabetes.<sup>21</sup>

The children were divided into four groups according to their changes of SDS-BMI in the time period of one year:

- Group I: increase in SDS-BMI
- Group II: decrease in SDS-BMI <0.25
- Group III: decrease in SDS-BMI ≥0.25 –<0.5
- Group IV: decrease in BMI ≥0.5.

Statistical analysis was performed by Winstat for Excel. Statistically significant differences were tested by the non-parametric Wilcoxon test for paired observation. Values are expressed as mean and standard deviation (SD).

## RESULTS

A total of 130 children (mean age 10.7 years, range 4–15 years; 53% girls; mean SDS-BMI 2.5, range 2.0–4.0) were included in the study. At baseline, 81 (62%) children had at least one unfavourable atherogenic risk factor (see table 1).

The four groups did not differ in terms of age, gender, degree of overweight (SDS-BMI), or cardiovascular risk factors.

The changes of the atherogenic risk-factor profile and insulin resistance are shown in tables 2–5. An increase in SDS-BMI (group I, see table 2) was associated with a significant increase in insulin resistance (HOMA), while systolic blood pressure, LDL cholesterol, and triglycerides showed a non-significant increase. A decrease in SDS-BMI of ≥0.5 (group IV, see table 5) was associated with a significant decrease in systolic and diastolic blood pressure, LDL serum cholesterol, triglycerides, and insulin resistance (HOMA) while HDL serum cholesterol increased significantly. In group IV, systolic blood pressure decreased by a mean of 21 (SD 11) mm Hg and diastolic blood pressure decreased by a mean of 9 (SD 14) mm Hg in children suffering from hypertension (n = 21). LDL cholesterol decreased by a mean of 28 (SD 36) mg/dl and triglycerides decreased by a mean of 82 (SD 31) mg/dl while HDL increased by a mean of 9 (SD 6) mg/dl in children in group IV suffering from dyslipidaemia (n = 15). Apart from a decrease in LDL cholesterol in group III (see table 4) there was no improvement in the parameters studied in groups I, II, and III.

## DISCUSSION

This is the first study on children concerning the changes of the cardiovascular risk factor profile in obesity in relation to

**Table 2** Group I (increasing SDS-BMI): SDS-BMI, BMI, systolic and diastolic blood pressure, LDL and HDL cholesterol, triglycerides, and insulin resistance (HOMA) at baseline, one year later, and the changes between these time points in 20 children

	Baseline	One year later	Changes	p value
SDS-BMI	2.4 (0.5)	2.6 (0.5)	+0.2 (0.2)	<0.001
BMI	27.9 (5.4)	30.0 (6.4)	+2.1 (1.9)	<0.001
Systolic blood pressure (mm Hg)	121 (16)	125 (18)	+4 (16)	0.191
Diastolic blood pressure (mm Hg)	63 (9)	65 (10)	+2 (10)	0.408
LDL cholesterol (mg/dl)	101 (30)	108 (32)	+6 (19)	0.324
HDL cholesterol (mg/dl)	47 (8)	50 (12)	+3 (11)	0.300
Triglycerides (mg/dl)	132 (81)	134 (132)	+3 (81)	0.681
HOMA	4.3 (3.1)	7.4 (7.6)	+3.1 (7.5)	0.021

Data presented as mean (SD).

**Table 3** Group II (decreasing SDS-BMI <0.25): SDS-BMI, BMI, systolic and diastolic blood pressure, LDL and HDL cholesterol, triglycerides, and insulin resistance (HOMA) at baseline, one year later, and the changes between these time points in 33 children

	Baseline	One year later	Changes	p value
SDS-BMI	2.7 (0.5)	2.6 (0.5)	–0.1 (0.1)	<0.001
BMI	31.4 (7.5)	30.9 (6.6)	–0.4 (1.7)	0.437
Systolic blood pressure (mm Hg)	131 (23)	125 (20)	–6 (17)	0.097
Diastolic blood pressure (mm Hg)	70 (13)	65 (12)	–5 (16)	0.060
LDL cholesterol (mg/dl)	119 (50)	114 (42)	–4 (28)	0.512
HDL cholesterol (mg/dl)	49 (11)	49 (13)	0 (11)	0.629
Triglycerides (mg/dl)	124 (68)	125 (73)	+1 (50)	0.945
HOMA	4.3 (3.0)	4.8 (3.4)	+0.5 (2.6)	0.241

Data presented as mean (SD).

**Table 4** Group III (decreasing SDS-BMI  $\geq 0.25$  up to  $<0.5$ ): SDS-BMI, BMI, systolic and diastolic blood pressure, LDL and HDL cholesterol, triglycerides, and insulin resistance (HOMA) at baseline, one year later, and the changes between these time points in 40 children

	Baseline	One year later	Changes	p value
SDS-BMI	2.5 (0.3)	2.1 (0.3)	-0.4 (0.1)	<0.001
BMI	28.0 (4.0)	26.9 (3.6)	-1.1 (1.1)	<0.001
Systolic blood pressure (mm Hg)	124 (19)	119 (16)	-4 (20)	0.182
Diastolic blood pressure (mm Hg)	63 (9)	62 (11)	-1 (14)	0.349
LDL cholesterol (mg/dl)	115 (32)	107 (28)	-8 (25)	0.040
HDL cholesterol (mg/dl)	47 (8)	48 (8)	+1 (9)	0.320
Triglycerides (mg/dl)	116 (53)	121 (60)	+5 (52)	0.888
HOMA	4.2 (3.0)	4.1 (2.1)	-0.1 (2.0)	0.893

Data presented as mean (SD).

**Table 5** Group IV (decreasing SDS-BMI  $\geq 0.5$ ): SDS-BMI, BMI, systolic and diastolic blood pressure, LDL and HDL cholesterol, triglycerides, and insulin resistance (HOMA) at baseline, one year later, and the changes between these time points in 37 children

	Baseline	One year later	Changes	p value
SDS-BMI	2.5 (SD 0.3)	1.7 (SD 0.4)	-0.8 (SD 0.3)	<0.001
BMI	26.5 (SD 3.8)	23.3 (SD 2.9)	-3.3 (SD 1.5)	<0.001
Systolic blood pressure (mm Hg)	123 (SD 18)	112 (SD 14)	-11 (SD 15)	<0.001
Diastolic blood pressure (mm Hg)	66 (SD 11)	60 (SD 9)	-6 (SD 15)	0.040
LDL cholesterol (mg/dl)	116 (SD 34)	109 (SD 32)	-7 (SD 26)	0.041
HDL cholesterol (mg/dl)	47 (SD 11)	51 (SD 11)	+4 (SD 11)	0.033
Triglycerides (mg/dl)	114 (SD 50)	94 (SD 32)	-20 (SD 43)	0.006
HOMA	3.1 (SD 2.0)	2.5 (SD 1.4)	-0.6 (SD 1.5)	0.019

Data presented as mean (SD).

the degree of weight reduction. In agreement with previous reports,<sup>7, 8</sup> our study showed that up to two thirds of our obese children already had one or more unfavourable cardiovascular risk factors.

In our sample, a significant improvement of cardiovascular risk factor profile associated with obesity (hypertension, increase in LDL cholesterol and triglycerides, decrease in HDL cholesterol) was shown due to a reduction of SDS-BMI of at least 0.5 over the time period of one year, while a reduction of SDS-BMI below showed no significant improvement except a lowering of LDL cholesterol in the group of children with a reduction of SDS-BMI of at least 0.25. A reduction of LDL cholesterol despite an improvement of other cardiovascular risk factors is probably caused by diet and not due to effective weight loss. Since hypertriglyceridaemia and decreased HDL cholesterol are stronger risk factors for atherogenesis than LDL cholesterol,<sup>22</sup> the clinical significance of decreased LDL cholesterol despite improvement of other cardiovascular risk factors is questionable.

A few studies on children based on short term weight loss over a few weeks showed an improvement of cardiovascular risk factor profile associated with obesity (reduction of hypertension, triglycerides, and LDL cholesterol).<sup>8, 12, 23, 24</sup> The only long term study to examine the cardiovascular risk profile, which comprised only a small number of patients (n = 20) showed no clinically important improvement five years after weight reduction with a significant increase in HDL cholesterol but no change in blood pressure, LDL cholesterol, and triglycerides.<sup>25</sup> The mean reduction of relative weight was 12.8% in this study. This small amount of weight loss (the mean reduction of relative weight was 22% in group IV of our sample) and the small sample may explain why there was no improvement of cardiovascular risk factor profile in the long term follow up.

The mean reduction of LDL cholesterol, triglycerides, and the increase of HDL cholesterol due to weight loss in children suffering from dyslipidaemia of group IV is comparable to the

effect of medical therapy such as simvastatin in children with familial hypercholesterolaemia.<sup>26, 27</sup> Prospective data of pharmacological therapy in dyslipidaemic obese children without familial hypercholesterolaemia are not available. The mean reduction of systolic and diastolic blood pressure due to weight loss in group IV was greater than the effects of medical therapies such as captopril in adults.<sup>28, 29</sup> There are no prospective data on the effect of medical therapy on blood pressure reduction in childhood obesity. In summary, the improvements in lipid profile and blood pressure seen in group IV are as clinically significant as might be achieved with pharmacological treatment, but without the concern about possible side effects.

The observed changes in the atherogenic risk factor profile in our sample represented the effects of a reduced fat intake and increased physical activity due to an ambulant training programme.<sup>15, 30</sup> Physical activity improves dyslipidaemia.<sup>31</sup> A reduction of triglycerides and LDL cholesterol has been reported in obese adolescents and adults on fat reduced diets.<sup>8, 32</sup> HDL cholesterol concentrations decrease during the period of dieting but tend to rise some months after the weight has stabilised at a reduced level.<sup>33, 34</sup>

The improvement of cardiovascular risk factor profile in reduction of overweight is attributed to improvement of insulin resistance.<sup>23, 24</sup> Insulin resistance is the main cause of hypertriglyceridaemia, decrease of HDL cholesterol, and increased blood pressure in obesity, and correlates to degree of overweight.<sup>22, 35</sup> The improvement of insulin resistance and the improvement of the cardiovascular risk factor profile could not be detected in our sample before a reduction of SDS-BMI of at least 0.5 over the time period of one year. In our sample, without weight reduction (group I) there was a significant increase in insulin resistance over the time period of one year, probably due to puberty progression<sup>36</sup> besides the effect of increasing overweight.

Even following such a wide ranging, costly programme as our "Obeldicks" training, only 28% of the participants can

achieve effective weight reduction with an improvement of the cardiovascular risk factor profile. In further studies, we could show that motivation was a strong predictor to therapy success<sup>30</sup> and the reduction in overweight was stable over a period of at least two years,<sup>16</sup> even if longer follow up is required.

In summary, the obese child's failure to achieve weight loss lead to an increase in insulin resistance after the time period of one year. An improvement of cardiovascular risk factor profile and insulin resistance is to be suspected after a reduction of BMI of at least 0.5.

# Authors' affiliations

T Reinehr, W Andler, Department of Vestische Kinderklinik, University of Witten-Herdecke, Datteln, Germany

# REFERENCES

- 1 Ebbeling CA, Pawlak DB, Ludwig DS. Childhood obesity: public-health crisis, common sense cure. *Lancet* 2002;**360**:473–82.
- 2 Mossberg HO. 40 year follow up of overweight children. *Lancet* 1989;**26**:491–3.
- 3 Jiang X, Srinivasan SR, Webber LS, et al. Association of fasting insulin level with serum lipid and lipoprotein levels in children, adolescents, and young adults: the Bogalosa Heart Study. *Arch Intern Med* 1995;**23**:190–6.
- 4 Facchini FS, Hua N, Abbasi F, et al. Insulin resistance as a predictor of age-related diseases. *J Clin Endocrinol Metab* 2001;**86**:3574–8.
- 5 Arslanian S, Suprasongsin C. Insulin sensitivity, lipids, and body composition in childhood: is "syndrome X" present? *J Clin Endocrinol Metab* 1996;**81**:1058–62.
- 6 Must A, Strauss RS. Risks and consequences of childhood and adolescent obesity. *Int J Obes* 1999;**23**(suppl 2):S2–11.
- 7 Csabi G, Török K, Jeges S, et al. Presence of metabolic cardiovascular syndrome in obese children. *Eur J Pediatr* 2000;**159**:91–4.
- 8 Wabitsch M, Hauner H, Heinze E, et al. Body-fat distribution and changes in atherogenic risk-factor profile in obese adolescent girls during weight loss. *Am J Clin Nutr* 1994;**60**:54–60.
- 9 Kiess W, Reich A, Muller G, et al. Clinical aspects of obesity in childhood and adolescence—diagnosis, treatment and prevention. *Int J Obes Relat Metab Disord* 2001;**25**(suppl 1):S75–9.
- 10 Institute of Medicine (IOM). Committee to develop criteria for evaluating the outcomes of approaches to prevent and treat obesity: Food and Nutrition Board; Institute of Medicine; Thomas PR (ed.). *Weighing the options—criteria for evaluating weight management programs*. Washington, DC: National Academy Press, 1995.
- 11 Cole TJ, Bellizzi MC, Flegal KM, et al. Establishing a standard definition for child overweight and obesity worldwide: international survey. *BMJ* 2000;**320**:1240–3.
- 12 Sung RYT, Yu CW, Chang SKY, et al. Effects of dietary intervention and strength training on blood lipid levels in obese children. *Arch Dis Child* 2002;**86**:407–10.
- 13 Reinehr T, Wollenhaupt A, Chahda C, et al. Ambulant training programs for obese children. Criteria of comparison for the development of valid therapy recommendations. *Klin Pädiatr* 2002;**214**:1–6.
- 14 Barlow SE, Dietz WH. Obesity evaluation and treatment: Expert Committee recommendations. The Maternal and Child Health Bureau, Health Resources and Services Administration and the Department of Health and Human Sciences. *Pediatrics* 1998;**102**:1–11.
- 15 Reinehr T. Das Adipositas-Schulungsprogramm OBELDICKS. In: Reinehr T, Dobe M, Kersting M, eds. *Therapie der Adipositas im Kindes- und Jugendalter. Das Adipositas-Schulungsprogramm OBELDICKS*. Göttingen: Hogrefe Verlag, 2003:18–53.
- 16 Reinehr T, Kersting M, Alexy U, et al. Long-term follow-up of overweight children: after training, after a single consultation session and without treatment. *J Pediatr Gastroenterol Nutr* 2003;**37**:72–4.
- 17 Kromeyer-Hauschild K, Wabitsch M, Geller F, et al. Percentiles of body mass index in children and adolescents evaluated from different regional German studies. *Monatsschr Kinderheilkd* 2001;**149**:807–18.
- 18 Cole TJ. The LMS method for constructing normalized growth standards. *Eur J Clin Nutr* 1990;**44**:45–60.
- 19 Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985;**28**:412–19.
- 20 Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. *Diabetes* 1998;**47**:1643–9.
- 21 Haffner SM, Gonzalez C, Miettinen H, et al. A prospective analysis of the HOMA model. *Diabetes Care* 1996;**19**:1138–41.
- 22 Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care* 2001;**24**:683–9.
- 23 Sotome MS, Despinase B, Bron A, et al. Lipid profiles of obese children and adolescents before and after significant weight loss; differences according to sex. *South Med J* 2000;**93**:278–82.
- 24 Epstein LH, Kuller LH, Wing RR, et al. The effect of weight control on lipid changes in obese children. *Am J Dis Child* 1989;**143**:454–7.
- 25 Knip M, Nuutinen O. Long-term effects of weight reduction on serum lipids and plasma insulin in obese children. *Am J Clin Nutr* 1993;**57**:490–3.
- 26 Dirisamer A, Hachemian N, Bucek RA, et al. The effect of low-dose simvastatin in children with familial hypercholesterolemia: a 1-year observation. *Eur J Pediatr* 2003;**162**:421–5.
- 27 De Jongh S, Ose L, Szamosi T, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. *Circulation* 2002;**106**:2231–7.
- 28 Hanson L, Hedner T, Lindholm L, et al. The Captopril Prevention Project (CAPPP) in hypertension—baseline data and current status. *Blood Press* 1997;**6**:365–7.
- 29 Wang JG, Staessen JA. Benefits of antihypertensive pharmacologic therapy and blood pressure reduction in outcome trials. *J Clin Hypertens* 2003;**5**:66–75.
- 30 Reinehr T, Brylak K, Alexy U, et al. Predictors to success in outpatient training in obese children and adolescents. *Int J Obes Relat Metab Disord* 2003;**27**:1087–92.
- 31 Kraus WE, Houmard J, Duscha B, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. *N Engl J Med* 2002;**347**:1483–92.
- 32 Skov AR, Toubro S, Ronn B, et al. Randomized trial on protein vs carbohydrate in ad libitum fat reduced diet for the treatment of obesity. *Int J Obes Relat Metab Disord* 1999;**23**:528–36.
- 33 Rössner S, Björvell H. Early and late effects of weight loss on lipoprotein metabolism in severe obesity. *Atherosclerosis* 1987;**64**:125–30.
- 34 Uusitupa MJ, Laakso M, Sarlund H, et al. Effects of very-low-caloric diet on metabolic control and cardiovascular risk factors in the treatment of obese non-insulin-dependent diabetics. *Am J Clin Nutr* 1990;**51**:768–73.
- 35 Reaven GM, Hoffman BB. A role for insulin in the aetiology and course of hypertension? *Lancet* 1987;**2**:435–7.
- 36 American Diabetes Association. Type 2 diabetes in children and adolescents. *Diabetes Care* 2000;**23**:381–9.
- 37 Report of the Second Task Force on Blood Pressure Control in Children—1987. Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda, Maryland. *Pediatrics* 1987;**79**:1–25.